CheckPoint 238 - Counter-Strike: NO!
Checkmate 238: Adjuvant checkpoint therapy after melanoma resection
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
Impact of CheckMate-238 Results for Patients With Melanoma
Dr. Weber on Biomarker Data From CheckMate-238 for Melanoma
How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care
Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma
7-year results from CheckMate 238: adjuvant nivolumab in melanoma
CheckMate 238: nivolumab versus ipilimumab in stage III melanoma
4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma
Dr. Weber on CheckMate-238 for Melanoma
Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma
Day 238: Fall of Jerusalem — The Bible in a Year (with Fr. Mike Schmitz)
Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma
Checkmate 238 results presented at ESMO 2017
Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS
Dr. Weber on Duration of Checkpoint Inhibitor Therapy in Melanoma
Dr. Weber on CheckMate-238 Compared to Other Trials in Melanoma
Dr. Weber Discusses Updated Data for CheckMate-238
Dr. Weber on the Future of Checkpoint Inhibitors in Melanoma
